Want to see TVTX full AI Analyst Report?
TVTX Stock Chart & Stats
$67.12
$0.68(1.20%)
At close: 4:00 PM EDT
$67.12
$0.68(1.20%)
Day’s Range― - ―
52-Week Range$22.59 - $68.73
Previous CloseN/A
Volume1.23M
Average Volume (3M)1.86M
Market Cap
$4.93B
Enterprise Value$5.44B
Total Cash (Recent Filing)$489.18M
Total Debt (Recent Filing)$616.90M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding94,261,086
10 Day Avg. Volume1,731,653
30 Day Avg. Volume1,864,117
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)29.69
Price to Sales (P/S)6.95
P/FCF Ratio-167.32
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue9.20
Enterprise Value/Gross Profit9.74
Enterprise Value/Ebitda941.21
Forecast
1Y Price Target
$75.92Price Target Upside13.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$729.52M
Bulls Say, Bears Say
Bulls Say
FILSPARI Commercial GrowthRapid FILSPARI growth across IgA nephropathy and FSGS demonstrates strong product adoption and expanding commercial reach. Continued demand growth can improve operating leverage, support reinvestment in the pipeline, and strengthen Travere’s position in rare kidney disease over the next several quarters.
Product Differentiation And IPClinical differentiation, durable extension data, and advancing method-of-use protection can reinforce physician and payer confidence in FILSPARI. These attributes may support continued prescribing, help defend the commercial franchise, and make the product’s revenue base more durable as competition develops.
Pipeline ExpansionA progressing Phase III program and the addition of civorebrutinib broaden Travere beyond its current commercial product. Pipeline diversification creates potential future growth avenues, increases the value of the rare-disease platform, and reduces reliance on a single marketed therapy over time.
Bears Say
Very High LeverageThe sharply increased debt burden and thin equity base leave limited protection against operating setbacks. Although cash generation has improved, substantial leverage can constrain investment flexibility, increase refinancing exposure, and direct future cash toward financing obligations rather than growth.
Profitability Not Yet DurableRevenue growth and high gross margins have not yet translated into consistent bottom-line or operating profitability. Persistent losses and only marginal EBITDA leave less internal funding for pipeline investment and make sustainable earnings dependent on further scale, expense discipline, and commercial execution.
Competitive And Access PressureNew entrants can increase competition for prescribers, patients, and payer coverage, potentially raising the commercial effort needed to sustain FILSPARI growth. Ongoing education requirements may lengthen adoption and increase selling complexity, especially as Travere expands across distinct kidney disease indications.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $22.59 and its highest was $68.73 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $4.93B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Feb 25, 2027 which is in 124 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Aug 04, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.235.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 94,261,086 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went down -0.285%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.92 (13.11% Upside)
$75.92 (13.11% Upside)
Blogger Sentiment
Neutral
TVTX Sentiment 56%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 612.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.79%
12-Months-Change
Fundamentals
Return on Equity
-55.79%
Trailing 12-Months
Asset Growth
43.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
TVTX Company Deck
TVTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and a positive growth trajectory: record FILSPARI demand and revenue, an encouraging FSGS launch that outpaced early IgA nephropathy uptake, meaningful pipeline additions (pegtibatinase and civorebrutinib), an IP allowance for IgAN methods, and a reinforced balance sheet following convertible refinancing. Offsetting items include elevated operating expenses, a $40M inducement expense, a $112.5M upfront payment for civorebrutinib (post-quarter), expected higher gross-to-net discounts in H2, and limited disclosure of granular commercial metrics and FSGS-specific IP outcomes. On balance, the strengths and growth drivers substantially outweigh the near-term costs and disclosure gaps reported in the quarter.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$75.92
▲(13.11% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Omeros
―
Aurinia Pharmaceuticals
―
Immunovant
―
Vera Therapeutics
―
Ownership Overview
1.50% Insiders
38.64% Mutual Funds
1.77% Other Institutional Investors
39.69% Public Companies and
Individual Investors